Clinical Trial Update: Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating pembrolizumab for recurrent Primary Central Nervous System Lymphoma. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Prof. Dr. Matthias Preusser | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: UNKNOWN